GI
FDMT icon

GAMMA Investing’s 4D Molecular Therapeutics FDMT Stock Holding History

GAMMA Investing’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7K Buy
1,334
+147
+12% +$1.43K ﹤0.01% 2899
2026
Q1 		$11.1K Sell
1,187
-464
-28% -$4.04K ﹤0.01% 3017
2025
Q4 		$12.4K Buy
1,651
+501
+44% +$5.08K ﹤0.01% 2872
2025
Q3 		$9.99K Buy
1,150
+1,142
+14,275% +$6.83K ﹤0.01% 2877
2025
Q2 		$30 Hold
8
– – ﹤0.01% 3766
2025
Q1 		$26 Hold
8
– – ﹤0.01% 3788
2024
Q4 		$45 Sell
8
-32
-80% -$251 ﹤0.01% 3766
2024
Q3 		$432 Sell
40
-1
-2% -$17 ﹤0.01% 3413
2024
Q2 		$861 Sell
41
-36
-47% -$903 ﹤0.01% 3095
2024
Q1 		$2.45K Buy
77
+21
+38% +$536 ﹤0.01% 2691
2023
Q4 		$966 Buy
+56
New +$737 ﹤0.01% 2797

Other funds holding FDMT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's FDMT Position: Q2 2026 in Review

GAMMA Investing increased its 4D Molecular Therapeutics (FDMT) stake by 12% in Q2 2026, buying an estimated $1.43K and bringing the position to 1,334 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

GAMMA Investing first reported a position in FDMT in Q4 2023 and has held it in 11 quarters since. 9 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • GAMMA Investing held 1,334 shares of 4D Molecular Therapeutics worth $17.7K as of Q2 2026.
  • GAMMA Investing bought 147 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.43K.
  • 4D Molecular Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2899 holding.
  • GAMMA Investing first reported a position in 4D Molecular Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 9 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.